The Nektar Therapeutics (NKTR) Receives “Buy” Rating from the Aegis

The Nektar Therapeutics (NKTR) Receives “Buy” Rating from the Aegis

Aegis restated their buy rating on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research report report published on Wednesday. The brokerage currently has a $21.00 price objective on the biopharmaceutical company’s stock.

Other research analysts also recently issued reports about the stock. Jefferies Group reissued a buy rating on shares of Nektar Therapeutics in a research note on Thursday, September 8th. Piper Jaffray Cos. set a $25.00 price target on shares of Nektar Therapeutics and gave the stock a buy rating in a research note on Monday, December 12th. Brean Capital reissued a buy rating and set a $23.00 price target on shares of Nektar Therapeutics in a research note on Friday, September 30th. Finally, Zacks Investment Research raised shares of Nektar Therapeutics from a sell rating to a hold rating in a research note on Thursday, September 29th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $20.50.

Nektar Therapeutics (NASDAQ:NKTR) opened at 12.18 on Wednesday. The company’s market capitalization is $1.86 billion. The company’s 50-day moving average is $13.00 and its 200 day moving average is $15.35. Nektar Therapeutics has a 52 week low of $10.52 and a 52 week high of $19.98.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.04. Nektar Therapeutics had a negative net margin of 98.87% and a negative return on equity of 8,769.15%. The business earned $36.30 million during the quarter, compared to analyst estimates of $32.42 million. During the same period in the previous year, the business posted ($0.06) earnings per share. Nektar Therapeutics’s revenue for the quarter was down 39.4% on a year-over-year basis. On average, analysts forecast that Nektar Therapeutics will post ($1.07) EPS for the current fiscal year.

In other news, Director R Scott Greer bought 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 24th. The shares were bought at an average cost of $13.50 per share, with a total value of $202,500.00. Following the completion of the purchase, the director now directly owns 121,333 shares in the company, valued at $1,637,995.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Howard W. Robin sold 87,500 shares of Nektar Therapeutics stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $17.06, for a total transaction of $1,492,750.00. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Nektar Therapeutics by 2.7% in the second quarter. Vanguard Group Inc. now owns 11,650,468 shares of the biopharmaceutical company’s stock valued at $165,787,000 after buying an additional 301,245 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Nektar Therapeutics by 7.3% in the third quarter. BlackRock Fund Advisors now owns 10,970,974 shares of the biopharmaceutical company’s stock valued at $188,481,000 after buying an additional 749,496 shares during the last quarter. RA Capital Management LLC increased its position in shares of Nektar Therapeutics by 13.6% in the third quarter. RA Capital Management LLC now owns 3,664,154 shares of the biopharmaceutical company’s stock valued at $62,950,000 after buying an additional 439,300 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of Nektar Therapeutics by 1.9% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 3,353,625 shares of the biopharmaceutical company’s stock valued at $57,615,000 after buying an additional 61,918 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Nektar Therapeutics by 3.2% in the third quarter. Bank of New York Mellon Corp now owns 1,825,071 shares of the biopharmaceutical company’s stock valued at $31,355,000 after buying an additional 56,079 shares during the last quarter. 85.85% of the stock is currently owned by institutional investors.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

Related posts

Leave a Comment